Diana Gulei

Iuliu Hațieganu University of Medicine and Pharmacy — Romania

Biochemistry, Genetics and Molecular Biology · Life Sciences

34h-index4.6kcitations102works10.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

MicroRNA in disease regulation(21), Cancer-related molecular mechanisms research(16), Circular RNAs in diseases(15), CAR-T cell therapy research(10), Acute Myeloid Leukemia Research(7)

Publications102 total

Proteolysis targeting chimeric-based technology in myeloma and lymphoma
Molecular Cancer Therapeutics·2026Open Access
Advances in measurable residual disease assessment for acute myeloid leukemia: from cytogenetics and molecular biology to assessment of the methylation pattern and surface-enhanced Raman scattering as emerging technologies
Biomarker Research·2025· 1 citedOpen Access
CARing about autoimmune disorders. Use of chimeric antigen receptor engineered T-cells in autoimmune diseases
Blood Reviews·2025Open Access
AML-022: SERS for Acute Promyelocytic Leukemia
Clinical Lymphoma Myeloma & Leukemia·2025
POSTER: AML-022 SERS for Acute Promyelocytic Leukemia
Clinical Lymphoma Myeloma & Leukemia·2025
Targeting degradation of IKZF1 and IKZF3 through modulation of the E3 ligase substrates in the context of cellular therapies for multiple myeloma
Biomarker Research·2025· 2 citedOpen Access
Comprehensive view on chemotherapy-free management of acute myeloid leukemia by using venetoclax in combination with targeted and/or immune therapies
Cell Death Discovery·2025· 4 citedOpen Access
Challenges in the preclinical design and assessment of CAR-T cells
Frontiers in Immunology·2025· 5 citedOpen Access
Humanized mouse models in MDS
Cell Death and Disease·2025· 1 citedOpen Access
Adoptive cellular therapies in multiple myeloma
Best Practice & Research Clinical Haematology·2025Open Access
Adoptive cellular therapies in non-Hodgkin lymphomas
Best Practice & Research Clinical Haematology·2025Open Access
Epigenetic Therapies in Melanoma—Targeting DNA Methylation and Histone Modification
Biomedicines·2025· 9 citedOpen Access
<scp>SERS</scp>‐Based Assessment of <scp>DNA</scp> Methylation for the Evaluation of Measurable Residual Disease in Acute Promyelocytic Leukaemia
Journal of Cellular and Molecular Medicine·2025· 3 citedOpen Access
Therapeutic advances in the targeting of ROR1 in hematological cancers
Cell Death Discovery·2024· 17 citedOpen Access
5-Azacytidine treatment inhibits the development of lung cancer models via epigenetic reprogramming and activation of cellular pathways with anti-tumor activity
Medicine and Pharmacy Reports·2024· 2 citedOpen Access
<scp>RNA</scp> methylation sequencing shows different gene expression signatures for response to azacytidine therapy in high‐grade myelodysplastic syndromes
Journal of Cellular and Molecular Medicine·2024· 1 citedOpen Access
Therapeutic advances of targeting receptor tyrosine kinases in cancer
Signal Transduction and Targeted Therapy·2024· 167 citedOpen Access
Impact of assessing the emotional health status in the management of cancer patients
Medicine and Pharmacy Reports·2024Open Access
In vivo imaging system (IVIS) therapeutic assessment of tyrosine kinase inhibitor-loaded gold nanocarriers for acute myeloid leukemia: a pilot study
Frontiers in Pharmacology·2024· 3 citedOpen Access
miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2.
PubMed·2024Open Access
page 1 of 6Next →

Frequent Co-authors

Ioana Berindan‐Neagoe(42), Cornelia Braicu(14), Roxana Cojocneanu(11), Lajos Ráduly(10), Atanas G. Atanasov(9), Alina‐Andreea Zimța(9), Alexandru Irimie(7), Călin Ionescu(7), Adrian Bogdan Țigu(7), Cristian Moldovan(7), Seyed Mohammad Nabavi(7), Lorand Magdo(6), Ciprian Tomuleasa(6), Raluca Munteanu(6), Anca Onaciu(6), Cecilia Bica(5), Alexandra Iulia Irimie(5), Nikolay Mehterov(5), Seyed Fazel Nabavi(5), Ancuța Jurj(5)